Evidence map›Paper›PMID 42559295›Full record

ArticleTheranostics2026

Clinically accessible drug-based nano-assemblies with self-targeting ability for NIR-II fluorescence imaging-guided surgery in triple-negative breast cancer.

Ruiqin Yang, Kangliang Lou, Shuangyan Bao, Chen Yang, Yating Gai, Shuanglong Chen, Qingmo Yang, Siqi Qiu, Yilong Lin, Hairong Zhao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruiqin YangDepartment of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
Kangliang LouDepartment of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Shuangyan BaoYunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali 671003, China.
Chen YangYunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali 671003, China.
Yating GaiXiamen Institute for Food and Drug Control, Xiamen 361012, China.
Shuanglong ChenDepartment of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
Qingmo YangDepartment of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
Siqi QiuDiagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou 515031, China.
Yilong LinDepartment of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361003, China.
Hairong ZhaoYunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali 671003, China.
Yang LiState Key Laboratory of Structural Chemistry & CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350108, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Accurate intraoperative visualization is critical for reducing margin positivity during breast-conserving surgery for triple-negative breast cancer (TNBC). Second near-infrared (NIR-II) fluorescence imaging represents a promising approach for precision surgery by combining lesion detection with real-time guidance. Nevertheless, the clinical translation of most fluorescence agents remains hampered by carrier-related toxicity and complex synthesis. Therefore, a "green" drug-repurposing strategy was adopted here to construct carrier-free pure-drug nano-assemblies (PDNAs), aiming to provide a biocompatible and precise intraoperative navigation tool for TNBC resection. Methods: We developed a novel PDNA system (CF-ICG) formed by the simple self-assembly of two clinically employed drugs: calcium folinate and indocyanine green. The targeting specificity of CF-ICG and the feasibility of NIR-II fluorescence-guided surgery were validated using MDA-MB-231-Luc xenograft and MMTV-PyVT transgenic models. A rapid Results: Driven by intrinsic Ca Conclusions: By combining a "green" fabrication process with a drug-repurposing strategy, we developed CF-ICG as a carrier-free PDNA with tumor self-targeting capability, enabling precise intraoperative navigation in preclinical models and

Indexed as

Optical ImagingSurgery, Computer-AssistedTriple Negative Breast NeoplasmsAnimalsCell Line, TumorFemaleFluorescent DyesHumansIndocyanine GreenMDA-MB-231 CellsMiceMice, TransgenicFluorescent DyesIndocyanine Greenbreast cancerFRα-targeted imagingNIR-II fluorescence imaging-guided surgerypure-drug nano-assembliessurgical margin

Identifiers

PMID42559295
PMCPMC13440617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.